Prognostic Significance of Fc Receptor-like 1 in Patients with Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, and Various B-cell Non-Hodgkin's Lymphoma
This study examined the expression pattern of FCRL1 in B-cell non-Hodgkin's lymphoma patients using real-time PCR and flow cytometry. The results revealed higher levels of FCRL1 expression in diffuse large B-cell lymphoma, hairy cell leukemia, and Burkitt lymphoma patients compared with control groups. There was a significant reduction in the levels of FCRL1 expression in chronic lymphocytic leukemia and mantle cell lymphoma patients compared with healthy individuals. These findings suggest FCRL1 as an excellent marker for the prognosis or immunotherapy of B-cell malignancies.
Publication date: 17 September 2019Source: Cell Reports, Volume 28, Issue 12Author(s): Anetta Ptasinska, Anna Pickin, Salam A. Assi, Paulynn Suyin Chin, Luke Ames, Roberto Avellino, Stephan Gröschel, Ruud Delwel, Peter N. Cockerill, Cameron S. Osborne, Constanze BoniferSummaryAcute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maintenance of t(8;21) AML is depend...
Authors: Petrakis I, Kontogiorgis C, Nena E, Athanasakis K, Gougoula V, Kotsianidis I, Constantinidis TC Abstract Introduction: Real-world effectiveness of hemato-oncology pharmaceuticals may not necessarily mimic clinical trial efficacy results, mainly due to demographic and clinical practice variability. The aim of this review was to systematically assess the availability of real-world evidence (RWE) and the transferability of clinical trial (CT) efficacy results to real life, for novel agents recently approved to manage lymphomas, leukemias and multiple myeloma. This is the largest cross-indication review compar...
Authors: Ahmed SR, Petersen E, Patel R, Migden MR Abstract INTRODUCTION: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Areas Covered: We review CSCC and the studies leading to cemiplimab's approval, including common side effects and safety issues experienced during the clinical trials. Expert Opini...
Condition: Acute Myeloid Leukemia Interventions: Drug: Gemtuzumab Ozogamicin 147; Drug: Gemtuzumab Ozogamicin 1; Drug: Glasdegib; Drug: Placebo Oral Tablet Sponsor: University Hospital Heidelberg Not yet recruiting
Conditions: Hepatocellular Carcinoma; Hepatoblastoma Interventions: Genetic: TEGAR T cells; Drug: Cytoxan; Drug: Fludarabine Sponsors: Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System Not yet recruiting
Condition: Hematological Malignancy Intervention: Genetic: Genetically engineered NK cells Sponsor: Fate Therapeutics Not yet recruiting
Conditions: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes Intervention: Drug: ASTX727 Sponsor: Astex Pharmaceuticals, Inc. Not yet recruiting
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma Intervention: Drug: Ibrutinib Sponsors: The First Affiliated Hospital with Nanjing Medical University; Xian-Janssen Pharmaceutical Ltd. Recruiting
Conditions: B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma Intervention: Biological: Tisagenlecleucel Sponsor: Novartis Pharmaceuticals Not yet recruiting
Condition: Non-hodgkin Lymphoma,B Cell Intervention: Drug: Acalabrutinib Sponsor: Seoul National University Hospital Recruiting